39629-86-2

Basic information

• Product Name: 5-OXO-1-PHENYL-PYRROLIDINE-3-CARBOXYLIC ACID
• Synonyms: TIMTEC-BB SBB010116;BUTTPARK 17\07-14;2-OXO-1-PHENYLPYRROLIDINE-4-CARBOXYLIC ACID;5-OXO-1-PHENYL-3-PYRROLIDINECARBOXYLIC ACID;5-OXO-1-PHENYL-PYRROLIDINE-3-CARBOXYLIC ACID;AKOS BB-6973;Albb-004698;5-oxo-1-phenylpyrrolidine-3-carboxylic acid(SALTDATA: FREE)
• CAS NO: 39629-86-2
• Molecular Formula: C₁₁H₁₁NO₃
• Molecular Weight: 205.21
• Product Categories: Carboxylic Acids;Pyrrolidines;Carboxylic Acids
• Mol File: 39629-86-2.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 494.6°C at 760 mmHg
• Flash Point: 252.9°C
• Appearance: /
• Density: 1.343g/cm³
• Vapor Pressure: 1.34E-10mmHg at 25°C
• Refractive Index: 1.606
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-OXO-1-PHENYL-PYRROLIDINE-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-OXO-1-PHENYL-PYRROLIDINE-3-CARBOXYLIC ACID(39629-86-2)
• EPA Substance Registry System: 5-OXO-1-PHENYL-PYRROLIDINE-3-CARBOXYLIC ACID(39629-86-2)

Safety Data

• Hazard Codes: Xi
• Statements: 43
• Safety Statements: 36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 39629-86-2(Hazardous Substances Data)

Usage

General Description

5-OXO-1-PHENYL-PYRROLIDINE-3-CARBOXYLIC ACID, also known as piracetam, is a synthetic chemical compound that belongs to the racetam family. It is a nootropic drug, meaning it is used to enhance cognitive function and improve memory and learning. Piracetam is thought to work by increasing blood flow and oxygen consumption in the brain, as well as modulating neurotransmitter levels. It is used to treat conditions such as dementia, Alzheimer's disease, and dyslexia, and is also used off-label as a cognitive enhancer by healthy individuals. Additionally, piracetam has been shown to have neuroprotective and anticonvulsant properties, and is generally well-tolerated with few side effects.

InChI:InChI=1/C11H11NO3/c13-10-6-8(11(14)15)7-12(10)9-4-2-1-3-5-9/h1-5,8H,6-7H2,(H,14,15)

Upstream product

• 62-53-3 aniline 
• 304859-13-0 [1-(3-anilino-2-hydroxypropyl)-4-piperidinyl]-(4-fluorophenyl)methanone 
• 97-65-4 2-methylenesuccinic acid 

Downstream Products

• 64320-92-9 methyl 5-oxo-1-phenylpyrrolidine-3-carboxylate 
• 915390-66-8 N-[(1R)-1-(1-naphthyl)ethyl]-5-oxo-1-phenylpyrrolidine-3-carboxamide 
• 892682-66-5 1-phenyl-4-(3-phenyl-1,2,4-oxadiazol-5-yl)pyrrolidin-2-one 
• 941960-48-1 C₁₉H₁₇N₃O₂ 
• 941960-51-6 C₁₈H₁₄ClN₃O₂ 
• 941917-62-0 C₁₈H₁₄FN₃O₂ 
• 941960-57-2 C₁₉H₁₇N₃O₃ 
• 915390-67-9 5-oxo-1-phenylpyrrolidine-3-carbaldehyde 

Relevant articles and documents

Synthesis and Biological Evaluation of Novel 5-Oxo-1-Phenylpyrrolidine-3-Carboxylic Acid Analogs

A number of 5-oxo-1-phenyl-4-(substituted methyl) pyrrolidine-3-carboxylic acid derivatives bearing pyrrolidine ring and methylamino residues in their structure were synthesized as potential antibacterial drugs. The chemical structures of all the compound

ANALGESIC DRUG USING PAC1 RECEPTOR ANTAGONISTIC DRUG

This invention relates to an analgesic drug comprising a compound represented by the following formula (I) or (II), wherein R1 is a C1-6-alkoxy group or a C1-6-haloalkoxy group; R2 is a hydrogen atom; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group; or a salt thereof, or a solvate thereof.

Synthesis of a novel and potent small-molecule antagonist of PAC1 receptor for the treatment of neuropathic pain

We recently identified novel small-molecule antagonists of the PACAP type I (PAC1) receptor using docking-based in silico screening followed by in vitro/vivo pharmacological assays. In the present study, we synthesized 18 novel derivatives based on the structure of PA-9, a recently developed antagonist of the PAC1 receptor, with a view to obtain a panel of compounds with more potent antagonistic and analgesic activities. Among them, compound 3d showed improved antagonistic activities. Intrathecal injection of 3d inhibited both pituitary adenylate cyclase-activating polypeptide (PACAP) and spinal nerve ligation-induced mechanical allodynia. The effects were more potent than PA-9. Compound 3d also showed anti-allodynic effects following oral administration. Hence, our results suggest that 3d may become an orally available analgesic in the treatment of the neuropathic pain.